Chris Viehbacher, Biogen CEO (Photo by Suzanne Kreiter/The Boston Globe via Getty Images)

April 24, 2024 11:18 AM EDT

8 takeaways from Biogen’s Q1 update: A ‘difficult’ launch for Leqembi, a $103M voucher and a focus on new licensing deals

Kyle LaHucik

Senior Reporter

Biogen’s leaders defended their Eisai-partnered Leqembi during a first-quarter earnings update on Wednesday, saying the Alzheimer’s treatment is on a path to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

8 takeaways from Biogen’s Q1 update: A ‘difficult’ launch for Leqembi, a $103M voucher and a focus on new licensing deals

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

8 take­aways from Bio­gen’s Q1 up­date: A ‘dif­fi­cult’ launch for Leqem­bi, a $103M vouch­er and a fo­cus on new li­cens­ing deals

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

8 takeaways from Biogen’s Q1 update: A ‘difficult’ launch for Leqembi, a $103M voucher and a focus on new licensing deals